BELLUS Health Inc (BLU)

Etorro trading 970x250
BELLUS Health Inc (BLU) Logo

About BELLUS Health Inc

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. The company was founded in 1993 and is headquartered in Laval, Canada. Address: 275 Armand-Frappier Boulevard, Laval, QC, Canada, H7V 4A7

BELLUS Health Inc News and around…

Latest news about BELLUS Health Inc (BLU) common stock and company :

Is the Options Market Predicting a Spike in BELLUS Health (BLU) Stock?
26 Nov, 2021 Yahoo! Finance

Investors need to pay close attention to BELLUS Health (BLU) stock based on the movements in the options market lately.

Bellus Health (BLU) Reports Q3 Loss
10 Nov, 2021 Yahoo! Finance

Bellus (BLU) delivered earnings and revenue surprises of -20.83% and 0.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

BELLUS Health Reports Third Quarter 2021 Financial Results and Business Highlights
10 Nov, 2021 FinancialContent

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders, today reported its financial and operating results for the third quarter ending September 30, 2021.

BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
10 Nov, 2021 FinancialContent

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will participate in fireside chats at two upcoming healthcare investor conferences.

BELLUS Health Convenes Virtual Analyst Event to Discuss the Chronic Cough Landscape and its Selective P2X3 Antagonist BLU-5937
01 Nov, 2021 FinancialContent

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders, today announced that it will convene a virtual analyst event to discuss the chronic cough landscape and its selective P2X3 antagonist, BLU-5937, on Monday, November 15, 2021 at 12:00 p.m. EST.

BELLUS Health Convenes Virtual Analyst Event to Discuss the Chronic Cough Landscape and its Selective P2X3 Antagonist BLU-5937
01 Nov, 2021 Yahoo! Finance

LAVAL, Quebec, November 01, 2021--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other hypersensitization-related disorders, today announced that it will convene a virtual analyst event to discuss the chronic cough landscape and its selective P2X3 antagonist, BLU-5937, on Monday, November 15, 2021 at 12:00 p.m. EST.

7 Biotech Penny Stocks With Huge Catalysts Coming in 2022
14 Oct, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips With a new year fast approaching, these biotech penny stocks may benefit from the shifting winds in the broader healthcare market. The post 7 Biotech Penny Stocks With Huge Catalysts Coming in 2022 appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

3 Biotech Stocks That Surged in September
05 Oct, 2021 FinancialContent

Find out why last month was a big one for these three drugmakers.

The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
29 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA ...

BLU December 17th Options Begin Trading
24 Sep, 2021 FinancialContent

Investors in BELLUS Health Inc (BLU) saw new options become available today, for the December 17th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 84 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

BELLUS (BLU) Completes Enrollment in Two Mid-Stage Studies
24 Sep, 2021 Yahoo! Finance

BELLUS (BLU) completes enrollment in the mid-stage studies for refractory chronic cough and chronic pruritus associated with atopic dermatitis.

BELLUS Health Announces Completion of Patient Enrollment in SOOTHE Phase 2b Trial for Refractory Chronic Cough and BLUEPRINT Phase 2a Trial for Chronic Pruritus Associated with Atopic Dermatitis
23 Sep, 2021 FinancialContent

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced that the Company has completed patient enrollment in the Phase 2b SOOTHE clinical trial of BLU-5937 in refractory chronic cough (“RCC”) and the Phase 2a BLUEPRINT clinical trial of BLU-5937 in chronic pruritus associated with atopic dermatitis (“AD”). Topline results from both trials are expected in December 2021.

Implied Volatility Surging for BELLUS Health (BLU) Stock Options
15 Sep, 2021 Yahoo! Finance

Investors need to pay close attention to BELLUS Health (BLU) stock based on the movements in the options market lately.

The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
15 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

46 Biggest Movers From Yesterday
15 Sep, 2021 FinancialContent

Gainers Communications Systems, Inc. (NASDAQ: JCS) jumped 39.4% to close at $9.41 on Tuesday as the company declared a special ...

Why BELLUS Health Is Trading Higher Today
14 Sep, 2021 FinancialContent

BELLUS Health(NASDAQ:BLU)shares are trading higher. The company on Monday announced interim analysis from the Phase 2b ...

Mid-Afternoon Market Update: Dow Tumbles 300 Points; Communications Systems Shares Climb
14 Sep, 2021 FinancialContent

Toward the end of trading Tuesday, the Dow traded down 0.87% to 34,565.88 while the NASDAQ fell 0.46% to 15,035.39. The S&P also ...

Mid-Day Market Update: FuelCell Energy Jumps After Q3 Results; RedHill Biopharma Shares Slide
14 Sep, 2021 FinancialContent

Midway through trading Tuesday, the Dow traded down 0.49% to 34,698.16 while the NASDAQ fell 0.05% to 15,098.38. The S&P also fell, ...

36 Stocks Moving In Tuesday's Mid-Day Session
14 Sep, 2021 FinancialContent

Gainers FuelCell Energy, Inc. (NASDAQ: FCEL) shares jumped 26% to $7.08 after the company reported better-than-expected Q3 ...

Mid-Morning Market Update: Markets Mostly Lower; US Annual Inflation Rate Slows to 5.3% in August
14 Sep, 2021 FinancialContent

Following the market opening Tuesday, the Dow traded down 0.26% to 34,778.27 while the NASDAQ rose 0.01% to 15,106.84. The S&P also ...

The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
14 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

72 Biggest Movers From Yesterday
14 Sep, 2021 FinancialContent

Gainers aTyr Pharma, Inc. (NASDAQ: LIFE) jumped 67% to settle at $9.15 on Monday as the company announced positive results from ...

What's Going On With BELLUS Health's Stock Today?
13 Sep, 2021 FinancialContent

BELLUS Health Inc (NASDAQ: BLU) is trading higher Monday after the companyannounced interim analysis from the Phase 2b SOOTHE ...

BELLUS Health Stock Shines After Refractory Chronic Cough Trial Data
13 Sep, 2021 FinancialContent

BELLUS Health Inc(NASDAQ: BLU) has announced apositive interim analysisfrom Phase 2b SOOTHE trial of BLU-5937 for ...

BELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic Cough
13 Sep, 2021 FinancialContent

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced positive findings from a preplanned administrative interim analysis of the ongoing Phase 2b SOOTHE trial of BLU-5937, the Company’s highly selective P2X3 antagonist, in patients with refractory chronic cough (“RCC”).

How Much Of BELLUS Health Inc. (TSE:BLU) Do Institutions Own?
12 Sep, 2021 Yahoo! Finance

If you want to know who really controls BELLUS Health Inc. ( TSE:BLU ), then you'll have to look at the makeup of its...

BELLUS Health to Present at the H.C. Wainwright Global Investment Conference
02 Sep, 2021 FinancialContent

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company at the H.C. Wainwright Global Investment Conference.

5 Penny Stocks To Watch For September With Upcoming Events
30 Aug, 2021 FinancialContent
BELLUS Health to Report Additional RELIEF Data in an Oral Presentation at the European Respiratory Society International Congress 2021
23 Aug, 2021 FinancialContent

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders, today announced that an abstract covering additional data from the RELIEF Phase 2a trial has been accepted for oral presentation at the upcoming European Respiratory Society (“ERS”) International Congress 2021, being held September 5-8, 2021.

Understanding BELLUS Health's Unusual Options Activity
12 Aug, 2021 FinancialContent

On Thursday, shares of BELLUS Health (NASDAQ:BLU) saw unusual options activity. After the option alert, the stock price moved up to ...

BELLUS Health Inc (BLU) is a NASDAQ Common Stock listed in , ,

970x250